1. Home
  2. CUE vs EDAP Comparison

CUE vs EDAP Comparison

Compare CUE & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.30

Market Cap

49.6M

Sector

Health Care

ML Signal

HOLD

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$3.21

Market Cap

75.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CUE
EDAP
Founded
2014
1979
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.6M
75.5M
IPO Year
2018
1997

Fundamental Metrics

Financial Performance
Metric
CUE
EDAP
Price
$0.30
$3.21
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$3.00
$8.50
AVG Volume (30 Days)
695.9K
62.4K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,100,000.00
$74,853,925.00
Revenue This Year
N/A
N/A
Revenue Next Year
$25.00
$2.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.61
52 Week Low
$0.23
$1.21
52 Week High
$1.75
$3.44

Technical Indicators

Market Signals
Indicator
CUE
EDAP
Relative Strength Index (RSI) 30.00 67.51
Support Level $0.23 $2.70
Resistance Level $0.51 $3.00
Average True Range (ATR) 0.05 0.33
MACD -0.01 0.04
Stochastic Oscillator 26.36 91.13

Price Performance

Historical Comparison
CUE
EDAP

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: